• Doctor of Medicine
  Kaohsiung Medical University School of Medicine,
  Kaohsiung, Taiwan, Republic of China

• Post-doctoral Research Fellowship,                        Vascular medicine & biology,
  Stanford University School of Medicine,
  Folk Cardiovascular Research Center,                      Stanford, California, USA 

• Contributing Physician, Taipei Veterans General Hospital

• Distinguish Professor                                                                                                    School of Medicine, National Yang Ming Chiao Tung University                                School of Medicine, Taipei, Taiwan, Republic of China
• Professor (Join appointment)                                                                  Institute of Pharmacology and Institute of Emergency,  and Critical Care Medicine, National Yang-Ming University University School of Medicine, Taipei, Taiwan,          Republic of China

• Republic of China

  Clinical Research Fellowship:  1991 - 1993
  Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Republic of China

  Attending Physician:  1993 - 2009
  Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Republic of China

  Board and Exacutive Secretary,   2009 - 2010
  Institutional Review Board (IRB), 
  Taipei Veterans General Hospital, Republic of China

  Professor and Director,
  Division of Clinical Skills Training,    2009 - 2013
  Department of Medical Research and Education, Taipei Veterans General Hospital, Republic of China

  Board and Exacutive Secretary,       2010 - 2015
  1st Institutional Review Board (IRB1), 
  Taipei Veterans General Hospital, Republic of China

  Professor and Director,
  Division of Clinical Research,        2013 
  Department of Medical Research
  Taipei Veterans General Hospital, Republic of China

• License of physician, Taiwan
• License of Cardiology,  Taiwan    

• Atherosclerosis
• Coronary artery disease and coronary intervention
• Hypertension
• Angiogenesis and endothelial progenitor cells
• Genetics and pharrmaco-genetics of cardiovascular diseases

• jwchen@vghtpe.gov.tw

1. Chang TT, Lin LY, Chen JW*. Inhibition of macrophage inflammatory protein-1β improves endothelial progenitor cell function and ischemia-induced angiogenesis in diabetes. Angiogenesis. 2019; 22(1):53-65.

2. Hsu CY, Tseng WK, Wu YW, Lin TH, Yeh HI, Chang KC, Wang JH, Chou RH, Huang CY, Huang PH, Leu HB*, Yin WH, Wu CC, Lin SJ, Chen JW*. Circulating TNFSf14 (tumor necrosis factor superfamily 14) predicts clinical outcome in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol. 2019 ;39(6):1240–1252.
3. Chang TT, Chen JW*. Hydralazine improves ischemia-induced neovasculogenesis viaxanthine-oxidase inhibition in chronic renal insufficiency. Pharmacol Res. 2020;151:104509.
4. Huang CC, Chang MT, Leu HB, Yin WH, Tseng WK, Wu YW, Lin TH, Yeh HI, Chang KC, Wang JH, Wu CC, Shyur LF*, Chen JW*. Association of arachidonic acid-derived lipid mediators with subsequent onset of acute myocardial infarction in patients with coronary artery disease. Sci Rep. 2020;10(1):8105.
5. Chang TT, Chiang CH, Chen C, Lin SC, Lee HJ, Chen JW*. Antioxidation and Nrf2-mediated heme oxygenase-1 activation contribute to renal protective effects of hydralazine in diabetic nephropathy. Biomed. Pharmacother. 2022; 151: 113139.

限於篇幅,以上謹為代表著作